Electronic Cigarettes clinical trials at UCSF

• Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes

  open to eligible people ages 21-70

  This is an observational, crossover design that will examine the pharmacokinetics and pharmacodynamics of impact of smoking tobacco cigarettes or vaping the JUUL electronic cigarette.

  San Francisco, California and other locations

• Short-Term Cardiovascular Effects of E-Cigarettes: Influence of Device Power

  open to eligible people ages 21 years and up

  This study will examine the short-term cardiovascular (CV) effects of e-cigarette device power in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette power on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.

  San Francisco, California and other locations

• Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH

  open to eligible people ages 21-70

  This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim of the study is to assess the impact of changes in e-liquid pH on nicotine pharmacokinetics, cardiovascular, and subjective effects of e-cigarettes.

  San Francisco, California and other locations

• Cigarette Harm Reduction With Electronic Cigarette Use

  Sorry, not yet accepting patients

  This is an observational, crossover study that will be examine use behaviors, chemical exposures, and biological effects of SREC compared to TC use in subjects confined to a research ward setting.

  San Francisco, California and other locations

Last updated: March 31, 2021